The discovery of anti-aquaporin-4 (AQP4) antibody (Ab) was essential for the evolution of NMO diagnostic criteria, leading to its reclassification as a member of a larger group of disorders called neuromyelitis optica spectrum disorders (NMOSD) (3). This evidence concerns the gene AQP4 and neuromyelitis optica.